Published in Hepatology on June 01, 2005
Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol (2008) 1.26
Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int (2010) 0.84
Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer (2014) 0.82
Plasminogen fragment K1-5 improves survival in a murine hepatocellular carcinoma model. Gut (2006) 0.80
Targeting of growth factors in the treatment of hepatocellular carcinoma: The potentials of polysaccharides. Oncol Lett (2017) 0.75
Targeting Hepatocellular Carcinoma: What did we Discover so Far? Oncol Rev (2016) 0.75
Plasminogen fragment K1-3 inhibits expression of adhesion molecules and experimental HCC recurrence in the liver. Int J Colorectal Dis (2009) 0.75
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Genome assembly comparison identifies structural variants in the human genome. Nat Genet (2006) 6.93
Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet (2003) 4.88
Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C. Gastroenterology (2002) 3.96
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology (2004) 2.45
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37
Interferon-lambda serum levels in hepatitis C. J Hepatol (2010) 2.28
p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut (2009) 2.20
Atypical Ormond's disease associated with bile duct stricture mimicking cholangiocarcinoma. Scand J Gastroenterol (2009) 2.17
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol (2012) 1.86
MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant (2005) 1.82
SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity (2006) 1.79
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
beta-Trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. Clin Chem (2005) 1.71
Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer (2008) 1.68
Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology (2012) 1.61
DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma (2006) 1.61
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol (2002) 1.60
Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology (2012) 1.60
Pseudomembranous and obstructive Aspergillus tracheobronchitis - optimal diagnostic strategy and outcome. Mycoses (2006) 1.58
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55
Comparative study of NK cell-mediated cytotoxicity using radioactive and flow cytometric cytotoxicity assays. J Immunol Methods (2005) 1.51
Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res (2004) 1.50
The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. Am J Pathol (2005) 1.48
Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion (2003) 1.48
Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS (2003) 1.47
Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int (2008) 1.46
Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. Am J Gastroenterol (2003) 1.46
Pitfalls in the diagnosis of intestinal tuberculosis: a case report. Scand J Gastroenterol (2005) 1.46
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Clinical outcome of subcentimeter non-small cell lung cancer after surgical resection: single institution experience of 105 patients. J Surg Oncol (2014) 1.43
Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol (2005) 1.42
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2003) 1.40
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer (2013) 1.40
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol (2011) 1.36
MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Cancer Lett (2011) 1.34
Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol (2012) 1.34
Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res (2009) 1.33
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc (2003) 1.27
Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol (2006) 1.26
Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. PLoS One (2013) 1.26
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology (2004) 1.24
An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology (2004) 1.24
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction. Circ Heart Fail (2010) 1.22
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther (2010) 1.21
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology (2010) 1.20
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Novel role for amphiregulin in protection from liver injury. J Biol Chem (2005) 1.19
Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res (2010) 1.19
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol (2010) 1.18
Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17
In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther (2003) 1.17
Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci (2010) 1.16
HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther (2005) 1.16
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology (2006) 1.16
Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology (2007) 1.15
Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in fulminant hepatitis B. Hepatology (2002) 1.15
Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther (2005) 1.15
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res (2006) 1.14
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol (2008) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One (2011) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13